Laboratory Characteristics in Chronic Atrophic Acrodermatitis

University Medical Centre Ljubljana

Status: Unknown

Conditions: Chronic Atrophic Acrodermatitis

Treatments: Drug: doxycycline orally, 100 mg, bid, 28 days; Drug: doxycycline orally, 100 mg, bid, 14 days

Study type: Interventional

Funder types: Other

Identifiers

NCT02147262

ACA-0613

Details and patient eligibility

About

The main objective of this study is to characterize the inflammatory proteins, gene polymorphisms, and transcriptome profiles in patients with chronic atrophic dermatitis to gain better insight into pathogenesis of chronic infection with Borrelia burgdorferi sensu lato.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• chronic atrophic dermatitis in patients >18 years

Exclusion criteria

• none

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

50 participants in 2 patient groups

ACA-doxy 14 days

Active Comparator group

Description:

patients with chronic atrophic acrodermatitis treated with doxycycline for 14 days

Treatment:

Drug: doxycycline orally, 100 mg, bid, 14 days

ACA-doxy 28 days

Active Comparator group

Description:

patients with chronic atrophic acrodermatitis treated with doxycycline for 28 days

Treatment:

Drug: doxycycline orally, 100 mg, bid, 28 days